THE ONLY FDA-Approved rFIX THERAPY THAT DELIVERS HIGH STEADY-STATE FACTOR LEVELS WITH UP TO 14-DAY DOSING*

IDELVION provides sustained, high-level protection for adult and pediatric patients with hemophilia B

Dosing schedule that meets your patients' needs

High and sustained Factor IX levels at steady state in clinical trials2,†

ACCESS THE PHARMACOKINETIC DATA

Zero median annualized spontaneous bleeding rate (AsBR) when dosed at 7 or 14 days in clinical trials

*In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month without spontaneous bleeding. Steady-state levels measured FIX at trough levels before each infusion every four weeks until week 92 at 7-day prophylaxis and week 104 at 14-day prophylaxis. FIX levels were 13% when dosed every 14 days.

RESOURCES FOR YOU AND YOUR PATIENTS

CSL Behring is committed to providing treatments and supportive services that make a meaningful difference in the lives of people with bleeding disorders.

Resources available to help ensure your patients get the treatment they need for hemophilia B include:

  • A free 30-day trial of IDELVION
  • Co-pay savings for IDELVION prescriptions and refills
  • Reimbursement and access support
LEARN MORE ABOUT IDELVION PATIENT SUPPORT
Call 1-800-676-4266 for IDELVION support
You are now leaving the current website.

Do you want to continue?

No Yes